Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGYXFP)

• Drug Name: BMS-582949 Drug Info
• Synonyms: BMS-582949; 623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; PS540446; BMS582949 free base; PS 540446

Indication

Disease Entry	ICD 11	Status	REF
Atherosclerosis	BD40	Phase 2	[1]
Psoriasis vulgaris	EA90	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 10409068
  ChEBI ID: CHEMBL1230065
  CAS Number: CAS 623152-17-0
  TTD Drug ID: DMGYXFP
  VARIDT Drug ID: DR00802

Molecule-Related Drug Atlas

Drug(s) Targeting Stress-activated protein kinase (p38)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-07265803	DM3E6Q4	Dilated cardiomyopathy	BC43.0	Phase 3	[3]
ARRY-797	DMJ48AB	Dilated cardiomyopathy	BC43.0	Phase 2	[4]
AZD7624	DMEW3K9	Chronic obstructive pulmonary disease	CA22	Phase 2	[5]
GSK2269557	DMIN0SV	Asthma	CA23	Phase 2	[6]
TAK-715	DMZKPI8	Rheumatoid arthritis	FA20	Phase 2	[7]
MW150	DMBRVXB	Alzheimer disease	8A20	Phase 2	[8]
LY-2228820	DMHXTNW	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[9]
PUR1800	DM6H10N	Chronic obstructive pulmonary disease	CA22	Phase 1	[10]
ARRY-614	DMXD93K	Arthritis	FA20	Discontinued in Phase 1	[11]
TA-5493	DMFES2K	Inflammation	1A00-CA43.1	Discontinued in Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein kinase unspecific (PK)	TTGFK5X	NOUNIPROTAC	Modulator	[2]
Stress-activated protein kinase (p38)	TTWELHI	NOUNIPROTAC	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7838).
• [2] Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33.
• [3] Clinical pipeline report, company report or official report of Pfizer
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
• [6] Evaluation of WO2012032067 and WO2012055846: two selective PI3Kdelta inhibitors, which is GSK-2269557. Expert Opin Ther Pat. 2012 Aug;22(8):965-70.
• [7] Inhibition of Wnt/beta-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Idelta/ . Chem Biol. 2011 Apr 22;18(4):485-94.
• [8] p38alpha MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10245-E10254.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959).
• [10] Clinical pipeline report, company report or official report of Pulmatrix Lexington, MA
• [11] Cmpany report (Arraybiopharma)
• [12] US patent application no. 2008,0269,123, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases.